SOSAFE
SoSafe, Europe’s largest security awareness and human risk management vendor, has appointed four new Executive Advisors. The advisors, comprised of industry experts and technology investors, will provide advice and strategic counsel to the SoSafe leadership team on its ambitious plans to expand their category and product leadership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529386435/en/
New hires Ilona Simpson, Carsten Thoma, Christian Karam, Sean Catlett (Photo: Business Wire)
With Forrester predicting that 90% of data breaches in 2024 will involve the human element, reducing human risk is what organisations need to prioritize for business continuity. SoSafe offers a technology-driven solution based on psychology and human-centric design. While SoSafe is committed to empowering digital self-defence around the world, the company is currently leading the category evolution from security awareness and training to human risk management. The Executive Advisors will support this transformative process from both an industry and organisational perspective to increase the company's speed to scale.
The following Executive Advisors will join:
Sean Catlett: Sean is the Chief Information Security and Trust Officer at Bumble. He also served as the Chief Security Officer at Slack, and as Chief Information Security Officer at Reddit and is an advisor to Balance Theory and Hampton North.
"It is clear that cybercriminals are effective at focusing on the human layer of security. AI-powered tools offer them solutions that scale attack success rates, intensifying cyber threats, and I believe the full potential is yet to be seen. We need comprehensive and effective solutions that counter these rising threats by sustainably empowering a strong security culture and reducing human risk - and SoSafe delivers just that in a new and innovative way", states Sean Catlett.
Christian Karam: Christian is an investor and senior advisor on technology investments, previously serving as the Deputy Group Chief Information Security Officer at UBS and the Head of Research & Innovation at INTERPOL.
“Cybercriminals continue to innovate rapidly, outpacing many organisations’ ability to keep up. Mere compliance training videos are no longer enough to overcome this challenge. We must rethink security awareness by building effective and robust security cultures that embrace continuous learning and treat mistakes as key drivers of resilience. SoSafe is leading this transformation towards holistic, people-centric human risk management, and I look forward to contributing to this journey”, says Christian Karam.
Ilona Simpson: Ilona is a trained psychologist and a long-standing CIO across a range of industries and companies, having worked at Netskope, adidas, EON, Aston Martin, DHL, and Porsche.
"We've made a lot of progress over the last few years in terms of the attention that senior management and boards are giving to the human layer of cybersecurity. For CIOs, the human factor and reducing human risk is top of mind. Now, they need effective and simple solutions to help them reduce human risk in a sustainable way”, states Ilona Simpson.
Carsten Thoma: Carsten is the President of Celonis. He has co-founded and scaled Hybris, sold to SAP and became President of SAP CX and member of the Global Executive Team. He serves as an advisor to La Famiglia/General Catalyst, and has been a long-standing investor and entrepreneur.
"SoSafe has the most promising foundation a young company can have: They are solving one of the most important business problems of our time in a fundamentally different way than their competitors. It's my ambition to help them succeed and, together with SoSafe's leadership team, build a global champion from Europe”, states Carsten Thoma.
“We are very honoured that some of the best minds in business and technology have agreed to serve as critical advisors to SoSafe. At this pivotal time in our development, their expertise will enable us to grow even faster, smarter, and more focused. I know I speak for the rest of the executive team when I say that we will value their experienced counsel as we look to accelerate our growth as a company”, states Dr Niklas Hellemann, Psychologist and CEO at SoSafe.
About SoSafe
SoSafe, founded by a team of behavioural scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioural science, SoSafe enhances secure behaviour across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defence by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 450 employees in seven locations: Cologne (headquarters), Amsterdam, Berlin, London, Paris, Lisbon, and Munich.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529386435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
